A key molecular mechanism drives the growth of liver cell cancer while simultaneously suppressing the body's immune response ...
More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...
News Medical on MSN
Engineered liver tissue model mimics early metabolic liver disease
More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...
Study suggests that persistently activated ATF6α is a tumor driver, a potential stratification marker for immunotherapy response, and a therapeutic target for HCC.
Leveraging human organoid-based mechanistic investigation, researchers reveal how an immunosuppressive drug, antithymocyte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results